Evidence map›Paper›PMID 41303508›Full record

ReviewInternational journal of molecular sciences2025

Targeting Cancer Through Thymoquinone: From Molecular Mechanisms to Clinical Prospects.

Nosayba Al-Damook, Molham Sakkal, Mostafa Khair, Walaa K Mousa, Ghalia Khoder, Rose Ghemrawi

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nosayba Al-DamookCollege of Pharmacy, Al Ain University, Abu Dhabi P.O. Box 112612, United Arab Emirates.ORCID 0000-0002-1149-4208
Molham SakkalCollege of Pharmacy, Al Ain University, Abu Dhabi P.O. Box 112612, United Arab Emirates.ORCID 0000-0001-6081-1284
Mostafa KhairCore Technology Platforms, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates.ORCID 0000-0001-6555-0642
Walaa K MousaCollege of Pharmacy, Al Ain University, Abu Dhabi P.O. Box 112612, United Arab Emirates.
Ghalia KhoderDepartment of Pharmaceutics and Pharmaceuticals Technology, College of Pharmacy, University of Sharjah, Sharjah P.O. Box 27272, United Arab Emirates.ORCID 0000-0002-6036-1022
Rose GhemrawiCollege of Pharmacy, Al Ain University, Abu Dhabi P.O. Box 112612, United Arab Emirates.ORCID 0000-0002-2465-0812

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thymoquinone (TQ), the active compound in Nigella sativa (black seed), has shown promising effects against cancer in many laboratory studies. In this review, we explore how TQ works on different aspects of cancer, from stopping cancer cell growth and spread, to triggering cancer cell death, reducing inflammation, and helping the immune system fight back. We also highlight how TQ may overcome one of the biggest problems in cancer treatment-chemoresistance. When used together with common treatments like chemotherapy, radiation, or immunotherapy, TQ has been shown to improve their effects and reduce harmful side effects in preclinical models. Our review further discusses how TQ affects cancer stem cells, the tumor environment, and gene regulation through epigenetics. While these findings are encouraging, the lack of human studies remains a major gap. We also address TQ's limited absorption and suggest ways to improve its delivery in the body, such as using nanoparticles or other carriers. Through this review, we aim to show the wide-ranging potential of TQ as a natural compound that may help make cancer treatments more effective and better tolerated. We call for clinical studies to take this research further and bring TQ closer to use in real-world cancer care.

Indexed as

BenzoquinonesNanoparticlesNeoplasmsNigella sativaAbsorptionAnimalsAutophagyHumansImmunotherapyNeoplastic Stem CellsOxidative StressTumor MicroenvironmentBenzoquinonesthymoquinoneanticancer agentscancer therapychemotherapy resistancecombination therapyThymoquinone

Identifiers

PMID41303508
PMCPMC12652967

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.